Deal value drops by 34.2 per cent in April 2025, compared to April 2024
GlobalData reveals the pharma and healthcare industry reported 81 deals worth $9.6 billion and 85 venture capital deals worth $2…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Novartis AG
Decoding the M&A landscape
Consolidation has emerged as a major trend as the pharma industry seeks new avenues of growth and looks to expand its existing…
M&A in pharma sees deals worth $14.8 bn in Nov 2024
According to GlobalData, M&A deal value declined by 2 per cent, and venture capital investments decreased by 5 per cent in…
Biocon expands its generic formulations, launches Everolimus tablets in US
Everolimus (Afinitor) is a prescription medication that is used to treat certain types of cancers and tumours
Novartis pays $729 million to settle US kickback charges
The Swiss drugmaker will pay $678 million to resolve claims it organized tens of thousands of sham educational events where it…
Novartis to test efficacy of old malaria drug against COVID-19
The company hopes to have data on its efficacy by June, a lead researcher for the trial told Reuters
Eris Lifesciences acquires trademark Zomelis (for Vildagliptin) from Novartis AG for India market
Zomelis is used in the treatment of type 2 diabetes and comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors